Polivy (Polatuzumab Vedotin-piiq)
- Medicine Name: Polivy
- Generic Name: Polatuzumab Vedotin-piiq
- Dosage Form & Strength: For injection: 30 mg or 140 mg of polatuzumab vedotin-piiq as a lyophilized powder in a single-dose vial
- Manufactured By: Genentech, Inc.
Polivy is a CD79b-directed antibody-drug conjugate used in combination with medicine bendamustine and a rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, following at least a couple of prior therapies.
Recommended Dosage: The recommended dose is 1.8 mg/kg as an intravenous infusion over 90 minutes every 21 days for 6 cycles along with bendamustine and a rituximab medicine. Subsequent infusions may be given over 30 minutes in case the previous infusion is tolerated. Premedicate with an antihistamine and antipyretic before polatuzumab vedotin injection. In case a planned dose is missed, administer as promptly as possible. Adjust the schedule of administration in order to maintain a 21-day interval b/w doses.
- Polatuzumab vedotin can cause peripheral neuropathy, including severe cases. Peripheral neuropathy appears as early as the first cycle of treatment and is a cumulative effect. Treatment may exacerbate pre-existing peripheral neuropathy. Assess patients for symptoms of peripheral neuropathy.
- Polatuzumab vedotin can cause infusion-related reactions, including severe cases. Administer an antihistamine and antipyretic before the use of Polatuzumab, and monitor patients precisely throughout the infusion. If an infusion-related reaction appears, interrupt the infusion and institute apt medical management.
- The polivy cancer treatment can cause serious or severe myelosuppression, including neutropenia, anemia and thrombocytopenia. Monitor CBC or complete blood counts throughout therapy. Cytopenias may require a delay, dose reduction, or interruption of therapy. Consider prophylactic G-CSFs administration.
- Fatal or serious infections, including opportunistic infections such as sepsis, pneumonia (including Pneumocystis jiroveci and other fungal pneumonia), cytomegalovirus infection, and herpesvirus infection have appeared in patients treated with Polatuzumab. Monitor patients during therapy for signs of infection. Administer prophylaxis for herpesvirus and Pneumocystis jiroveci pneumonia.
- PML has been reported after treatment with Polatuzumab injection. Assess for new or worsening neurological, cognitive, or behavioral changes. Hold this therapy and any concomitant chemotherapy in case PML is suspected, and permanently halt therapy if the diagnosis is confirmed.
- The polivy lymphoma may cause tumor lysis syndrome. Patients with high tumor burden and rapidly proliferative tumor may be at greater risk of tumor lysis syndrome. Monitor and consider appropriate measures, including tumor lysis syndrome prophylaxis.
- Severe cases of hepatotoxicity that were consistent with hepatocellular injury, including elevations of transaminases or bilirubin, have occurred in patients treated with medicine polivy. Preexisting liver disease, elevated baseline liver enzymes, and concomitant drugs may enhance the probability of hepatotoxicity. Monitor liver enzymes and bilirubin level.
- Depending on the mechanism of action and findings, this medicine can cause fetal harm if used by a pregnant woman. Females of reproductive age should use apt contraception during treatment and for at least three months after the final dose.
What documents are required to import POLIVY to India?
POLIVY® (polatuzumab vedotin-piiq) can be imported by patients or government hospitals on the name of the patients only.
The following documentations are needed to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Proof of Identity (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is POLIVY available in India?
POLIVY (polatuzumab vedotin-piiq injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of Polivy injection in India (Delhi, Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
POLIVY can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of POLIVY (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Polivy 140mg injection price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the POLIVY (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Polivy®?
Polatuzumab Vedotin-piiq is Generic Name for the trade name drug Polivy®.
What is the Manufacturer Name of Polivy®?
Polivy® is manufactured by Genentech, Inc.
Is Polivy® approved by the FDA?
Yes, Polivy® is approved by the FDA. Date of first approval: June 10, 2019
What is diffuse large B-cell lymphoma (DLBCL)?
DLBCL, is a type of aggressive lymphoma that affects B cells, which are WBCs that protect the body from infection. Although DLBCL may occur at any age, its occurrence increases with age. Most individuals are first diagnosed between the ages of 65 and 74. It can affect both men and women, although it is a bit more common in men.
What does relapsed or refractory (R/R) mean?
Relapse refers when the disease or the signs/symptoms of the disease come back after responding to previous therapy. Refractory refers to a disease that has not responded to previous therapy. Relapsed or refractory diffuse large B-cell lymphoma is often referred to as R/R DLBCL.
How is Polivy injection administered?
Polivy injection is administered as an IV infusion (directly into the vein) in a clinic or infusion center. Discuss with your health specialis in case you experience any adverse reactions during or after the infusion.
What are the most common side effects due to Polivy®?
The most common side effects during treatment were low blood cell counts, nerve problems in arms and legs, tiredness or lack of energy, diarrhea, nausea, decreased appetite, fever, and infections.
How much does Polivy 140 mg cost in India?
Polivy 140 mg injection cost in India is reasonable and can vary. In order to procure this DLBCL medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Polivy®?
Store refrigerated at 2-8°C (36-46°F) in original carton to protect from the light. Do not use beyond the expiration date shown on the carton. Neither freeze nor shake it.
What are the Highlights of prescribing information for Polivy®?
Click Here to download full polivy prescribing information.
Is it safe to buy Polivy® online from India?
Yes, You can buy Polivy injection online from India online authentically from https://theindianpharma.com/ if this product is not available or has not been approved in your home country.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.